Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Rating of “Hold” by Brokerages

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has earned an average recommendation of “Hold” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $3.33.

SYRS has been the subject of a number of analyst reports. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com assumed coverage on Syros Pharmaceuticals in a report on Friday. They set a “sell” rating for the company. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th.

Syros Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ SYRS opened at $0.21 on Monday. Syros Pharmaceuticals has a 12-month low of $0.18 and a 12-month high of $7.96. The stock’s fifty day simple moving average is $0.23 and its two-hundred day simple moving average is $1.95. The stock has a market capitalization of $5.67 million, a PE ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the company posted ($1.35) EPS. On average, equities analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 12.26% of the stock is currently owned by insiders.

Institutional Trading of Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned 0.06% of Syros Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.